Literature DB >> 30701218

Hodgkin's lymphoma in a patient on adalimumab treatment for psoriasis.

Nouf Alballa1, Alanoud Alyousef1, Albatool Alamari1, Ahmed Abdullah Alhumidi1, Mohammed Ayesh Zayed1, Leena Zeitouni1, Fahad Mohammed Alsaif1.   

Abstract

Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian cell expression system and is widely-known to treat a number of immune-mediated conditions, including psoriasis. There has been a growing concern regarding the possible association between TNF-alpha inhibitors and malignancy. In this case report, we describe the case of a 20-year-old woman, known to have been suffering from chronic plaque psoriasis for 12 years, and who developed Hodgkin's lymphoma within five weeks of beginning adalimumab treatment.

Entities:  

Keywords:  Adalimumab; Hodgkin’s lymphoma; psoriasis; tumor

Year:  2018        PMID： 30701218      PMCID： PMC6327155          DOI： 10.21037/acr.2018.12.01

Source DB:  PubMed          Journal:  AME Case Rep        ISSN： 2523-1995


  20 in total

Review 1.  Psoriasis--epidemiology and clinical spectrum.

Authors:  E Christophers
Journal:  Clin Exp Dermatol       Date:  2001-06       Impact factor: 3.470

2.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

3.  Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

Authors:  Anna K Wong; Susan Kerkoutian; Jonathan Said; Hooman Rashidi; Sheeja T Pullarkat
Journal:  Clin Rheumatol       Date:  2011-11-18       Impact factor: 2.980

Review 4.  New insights in the immunologic basis of psoriasis.

Authors:  Kristine E Nograles; Batya Davidovici; James G Krueger
Journal:  Semin Cutan Med Surg       Date:  2010-03

5.  Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.

Authors:  Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H Sasso
Journal:  J Am Acad Dermatol       Date:  2011-07-14       Impact factor: 11.527

6.  EBV-associated plasmablastic lymphoma in a patient with Crohn's disease after adalimumab treatment.

Authors:  Li Liu; Aline Charabaty; Metin Ozdemirli
Journal:  J Crohns Colitis       Date:  2012-08-17       Impact factor: 9.071

7.  Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

Authors:  Kim A Papp; Yves Poulin; Robert Bissonnette; Marc Bourcier; Darryl Toth; Leslie Rosoph; Melanie Poulin-Costello; Mike Setterfield; Jerry Syrotuik
Journal:  J Am Acad Dermatol       Date:  2010-09-17       Impact factor: 11.527

8.  The risk of lymphoma in patients with psoriasis.

Authors:  Joel M Gelfand; Daniel B Shin; Andrea L Neimann; Xingmei Wang; David J Margolis; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

Review 9.  Histologic mimickers of mycosis fungoides: a review.

Authors:  Kavitha Reddy; Jag Bhawan
Journal:  J Cutan Pathol       Date:  2007-07       Impact factor: 1.587

Review 10.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

Authors:  Antonella Di Cesare; Paola Di Meglio; Frank O Nestle
Journal:  J Invest Dermatol       Date:  2009-03-26       Impact factor: 8.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.